83 related articles for article (PubMed ID: 16364744)
1. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
Vogt PK; Bader AG; Kang S
Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic kinase signalling.
Blume-Jensen P; Hunter T
Nature; 2001 May; 411(6835):355-65. PubMed ID: 11357143
[TBL] [Abstract][Full Text] [Related]
6. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.
Kang S; Denley A; Vanhaesebroeck B; Vogt PK
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1289-94. PubMed ID: 16432180
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic PI3K deregulates transcription and translation.
Bader AG; Kang S; Zhao L; Vogt PK
Nat Rev Cancer; 2005 Dec; 5(12):921-9. PubMed ID: 16341083
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific mutations in phosphatidylinositol 3-kinase.
Vogt PK; Kang S; Elsliger MA; Gymnopoulos M
Trends Biochem Sci; 2007 Jul; 32(7):342-9. PubMed ID: 17561399
[TBL] [Abstract][Full Text] [Related]
12. PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role.
Utsugi M; Dobashi K; Ono A; Ishizuka T; Matsuzaki S; Hisada T; Shimizu Y; Kawata T; Aoki H; Kamide Y; Mori M
J Immunol; 2009 May; 182(9):5225-31. PubMed ID: 19380768
[TBL] [Abstract][Full Text] [Related]
13. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Granville CA; Memmott RM; Gills JJ; Dennis PA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
15. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Van Aller GS; Carson JD; Fernandes C; Lehr R; Sinnamon RH; Kirkpatrick RB; Tummino PJ; Luo L
Anal Biochem; 2008 Dec; 383(2):311-5. PubMed ID: 18814837
[TBL] [Abstract][Full Text] [Related]
16. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
Edling CE; Selvaggi F; Buus R; Maffucci T; Di Sebastiano P; Friess H; Innocenti P; Kocher HM; Falasca M
Clin Cancer Res; 2010 Oct; 16(20):4928-37. PubMed ID: 20876794
[TBL] [Abstract][Full Text] [Related]
17. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Georgakis GV; Younes A
Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
[TBL] [Abstract][Full Text] [Related]
18. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
[TBL] [Abstract][Full Text] [Related]
19. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
Kim D; Cheng GZ; Lindsley CW; Yang H; Cheng JQ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1250-8. PubMed ID: 16370391
[TBL] [Abstract][Full Text] [Related]
20. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.
De Gregorio G; Coppa A; Cosentino C; Ucci S; Messina S; Nicolussi A; D'Inzeo S; Di Pardo A; Avvedimento EV; Porcellini A
Oncogene; 2007 Mar; 26(14):2039-47. PubMed ID: 17043656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
